Ondine Biomedical Inc. (OBI.L)

6,75 0,00 (0,00%) Börsenschluss: 05:31PM BST

Ondine Biomedical Inc.

1100 Melville Street
Suite 888
Vancouver, BC V6E 4A6
Canada
604-669-0555
https://www.ondinebio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA	Founder, CEO & Executive Director	501,29k	N/A	N/A
Dr. Nicolas G. Loebel Ph.D.	President, CTO & Executive Director	585,65k	N/A	N/A
Dr. Simon Sinclair Ph.D.	Chief Medical Officer & Director	73,04k	N/A	1972
Mr. Kwong Choo CPA, CIMA	Interim Chief Financial Officer	N/A	N/A	N/A
Mr. William Kanz	Senior VP of Engineering & Operations	N/A	N/A	N/A
Angelika Vance	Vice President of Corporate Communications	N/A	N/A	N/A
Mr. Matt Ross	Vice President of Sales & Marketing	N/A	N/A	N/A
Ms. Elaine Lei CPA	Corporate Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in GBp.

Beschreibung

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection-based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces viral titres and transmission of respiratory viruses, such as SARS-CoV-2, influenza, RSV, etc.; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

Corporate Governance

Ondine Biomedical Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.